FDA examines cause of valsartan impurity
The US Food and Drug Administration (FDA) says a “major operation” is underway to investigate and address the “troubling finding” of a toxic impurity in some generic versions of valsartan that could cause cancer, leading the agency to also test all drugs in valsartan’s therapeutic class for traces of the toxic material.
You may also be interested in...
Release of several different safety announcements showcases US FDA Commissioner Gottlieb's efforts to quell potential public concerns with an active communication strategy.
Amazon’s motion to dismiss is pending in Washington State’s Western District in litigation concerning Prime subscriptions and alleged “dark patterns” used to trick consumers into enrolling and hinder cancellations, according to the US Federal Trade Commission. The case could be instructive for any and all digital marketers at a time of legal uncertainty surrounding the topic.
As FDA decision on Alzheimer’s product approaches, new paper outlines Lilly’s arguments for unfettered Medicare coverage for donanemab once it is approved.